Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)-0.14 Insider Own2.09% Shs Outstand173.40M Perf Week8.20%
Market Cap230.17M Forward P/E- EPS next Y-0.09 Insider Trans-2.15% Shs Float170.72M Perf Month7.76%
Income-24.43M PEG- EPS next Q-0.02 Inst Own61.86% Short Float2.01% Perf Quarter46.02%
Sales132.37M P/S1.74 EPS this Y49.97% Inst Trans-8.84% Short Ratio3.08 Perf Half Y10.92%
Book/sh-0.18 P/B- EPS next Y45.15% ROA-21.16% Short Interest3.42M Perf Year-14.29%
Cash/sh0.36 P/C3.69 EPS next 5Y- ROE-699.05% 52W Range0.71 - 1.96 Perf YTD-8.97%
Dividend Est.- P/FCF- EPS past 5Y11.34% ROI-86.34% 52W High-32.65% Beta0.91
Dividend TTM- Quick Ratio1.84 Sales past 5Y33.59% Gross Margin97.23% 52W Low85.39% ATR (14)0.09
Dividend Ex-Date- Current Ratio1.97 EPS Y/Y TTM70.77% Oper. Margin-14.40% RSI (14)57.21 Volatility7.67% 6.91%
Employees155 Debt/Eq- Sales Y/Y TTM48.11% Profit Margin-18.45% Recom2.33 Target Price4.12
Option/ShortYes / Yes LT Debt/Eq- EPS Q/Q70.39% Payout- Rel Volume0.90 Prev Close1.30
Sales Surprise3.44% EPS Surprise57.75% Sales Q/Q25.54% EarningsNov 07 AMC Avg Volume1.11M Price1.32
SMA2010.41% SMA502.46% SMA2009.53% Trades Volume1,005,828 Change1.54%
Date Action Analyst Rating Change Price Target Change
Apr-03-23Resumed Piper Sandler Neutral $2
Jun-09-22Downgrade Citigroup Buy → Neutral
Jun-08-22Downgrade Piper Sandler Overweight → Neutral $7 → $1
Jun-08-22Downgrade Cantor Fitzgerald Overweight → Neutral $6 → $1
Mar-23-22Initiated B. Riley Securities Neutral $4
Nov-09-20Downgrade JP Morgan Overweight → Neutral
Nov-15-19Resumed Cantor Fitzgerald Overweight $7 → $5
Sep-26-19Resumed JP Morgan Overweight $7
Mar-01-19Reiterated Cantor Fitzgerald Overweight $9 → $7
Aug-27-18Initiated Citigroup Buy $8.50
Feb-22-24 07:50AM
Feb-19-24 08:34AM
Jan-10-24 08:00AM
Jan-08-24 08:54AM
04:30PM Loading…
Jan-05-24 04:30PM
Jan-04-24 08:05AM
Jan-03-24 10:51AM
Dec-08-23 08:05AM
Nov-08-23 03:09PM
Nov-07-23 05:06PM
Nov-06-23 08:05AM
09:27AM Loading…
Nov-02-23 09:27AM
Oct-31-23 08:05AM
Oct-11-23 08:05AM
Oct-06-23 04:30PM
Sep-20-23 08:05AM
Aug-30-23 08:05AM
Aug-02-23 10:16AM
Aug-01-23 05:15PM
Jul-27-23 06:06PM
Jul-25-23 08:00AM
Jul-05-23 04:30PM
Jun-07-23 01:41PM
08:05AM Loading…
Jun-06-23 08:05AM
Jun-01-23 08:05AM
May-31-23 08:05AM
May-25-23 06:07AM
May-10-23 03:31PM
May-04-23 10:06AM
May-03-23 10:39AM
May-02-23 05:15PM
Apr-26-23 10:02AM
Apr-25-23 10:01AM
Apr-21-23 09:27AM
Apr-16-23 09:30AM
Apr-06-23 04:30PM
Mar-09-23 06:17AM
Mar-08-23 11:52AM
Mar-07-23 05:15PM
Feb-28-23 08:05AM
Feb-02-23 04:05PM
Jan-25-23 07:30AM
Jan-18-23 08:05AM
Jan-09-23 08:05AM
Dec-28-22 09:20AM
Dec-26-22 10:02AM
Dec-22-22 08:05AM
Dec-15-22 08:05AM
Dec-09-22 04:05PM
Dec-05-22 11:05AM
Dec-03-22 08:55AM
Dec-02-22 12:43PM
Dec-01-22 05:03PM
Nov-12-22 08:19AM
Nov-10-22 04:05PM
Nov-03-22 06:05PM
Nov-02-22 06:41AM
Nov-01-22 04:01PM
Oct-27-22 08:30AM
Oct-12-22 12:34PM
Oct-11-22 07:36AM
Oct-10-22 05:44PM
Sep-21-22 06:29AM
Sep-12-22 07:00AM
Sep-06-22 08:30AM
Aug-03-22 08:14AM
Aug-02-22 06:05PM
Jul-26-22 08:30AM
Jul-09-22 08:27AM
Jun-16-22 06:18AM
Jun-15-22 01:26PM
Jun-09-22 12:48PM
Jun-08-22 04:56PM
Jun-05-22 09:04AM
May-03-22 05:35PM
Apr-26-22 08:30AM
Apr-20-22 06:46AM
Apr-08-22 07:30AM
Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
RODRIGUEZ RAUL RCEO, PresidentFeb 05Sale1.1430,54534,8212,036,629Feb 06 08:18 PM
Santos David AEVP, Chief Commercial OfficerFeb 05Sale1.148,91810,167349,093Feb 06 08:18 PM
Schorno Dean LEVP & Chief Financial OfficerFeb 05Sale1.147,0278,011402,891Feb 06 08:18 PM
RODRIGUEZ RAUL RCEO, PresidentFeb 02Sale1.1322,34925,2612,067,174Feb 06 08:18 PM
Santos David AEVP, Chief Commercial OfficerFeb 02Sale1.135,6016,329358,011Feb 06 08:18 PM
Schorno Dean LEVP & Chief Financial OfficerFeb 02Sale1.135,6016,327409,918Feb 06 08:18 PM